DeFilipp Zachariah, Chen Yi-Bin
Blood. 2023 Jan 5;141(1):39-48. doi: 10.1182/blood.2021012412.
Disease relapse is the leading cause of failure for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo-HCT is a promising strategy to reduce the incidence of relapse and enhance the curative potential of allo-HCT. Research investigations and clinical applications of this approach have greatly increased in recent years, with an expanding number of available therapeutic agents to introduce in the posttransplant setting. However, many questions and challenges remain regarding the feasibility and clinical impact of maintenance. In this article, we present four common case scenarios addressing select available therapeutic agents as a framework to review published data and ongoing studies and describe our current standard practice in the rapidly evolving field of maintenance therapy after allo-HCT.
疾病复发是接受异基因造血细胞移植（allo-HCT）患者治疗失败的主要原因。allo-HCT后给予维持治疗是一种有前景的策略，可降低复发率并提高allo-HCT的治愈潜力。近年来，这种方法的研究调查和临床应用大幅增加，移植后可用的治疗药物数量不断增多。然而，关于维持治疗的可行性和临床影响仍存在许多问题和挑战。在本文中，我们呈现了四个常见病例场景，涉及选定的可用治疗药物，以此作为框架来回顾已发表的数据和正在进行的研究，并描述我们在allo-HCT后迅速发展的维持治疗领域中的当前标准做法。
